Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 8/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | PPME1 | Q9Y570 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | MET | P08581 | 1/20 | 0.44 |
| ▸ | APEH | P13798 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | PARL | Q9H300 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28139909 | 0.76 | PPME1 (0.51) | HTR6MEN1ALDH1A1LMNAHPGD | |
| SCHEMBL28189646 | 0.76 | HTR6 (0.50) | HTR6MEN1ALDH1A1LMNAHPGD | |
| SCHEMBL1599348 | 0.76 | HTR6 (0.50) | HTR6MEN1ALDH1A1LMNAHPGD | |
| SCHEMBL14760380 | 0.76 | HTR6 (0.50) | HTR6MEN1ALDH1A1LMNAHPGD | |
| SCHEMBL17900455 | 0.73 | PPME1 (0.49) | HTR6MEN1ALDH1A1LMNAHPGD | |
| SCHEMBL10176180 | 0.73 | HTR6 (0.47) | HTR6MEN1ALDH1A1LMNAHPGD | |
| SCHEMBL27662268 | 0.73 | PPME1 (0.49) | HTR6MEN1ALDH1A1LMNAHPGD | |
| SCHEMBL1616366 | 0.73 | PPME1 (0.60) | HTR6MEN1ALDH1A1LMNAHPGD | |
| SCHEMBL16469258 | 0.73 | ALDH1A1 (0.48) | HTR6MEN1ALDH1A1LMNAHPGD | |
| SCHEMBL10145004 | 0.72 | PPME1 (0.47) | HTR6MEN1ALDH1A1LMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150246030-A1 | Compounds Having CRTH2 Antagonist Activity | ATOPIX THERAPEUTICS LTD (GB) | 2015-09-03 | — | — | US | disclosed |
| US-8980927-B2 | Compounds having CRTH2 antagonist activity | ATOPIX THERAPEUTICS LIMITED (GB) | 2015-03-17 | — | — | US | disclosed |
| CN-101932571-B | Compounds having CRTH2 antagonist activity | OXAGEN LTD | 2014-04-23 | — | — | CN | disclosed |
| US-20140039012-A1 | Compounds Having CRTH2 Antagonist Activity | ATOPIX THERAPEUTICS LIMITED (GB) | 2014-02-06 | — | — | US | disclosed |
| US-8563536-B2 | Compounds having CRTH2 antagonist activity | ATOPIX THERAPEUTICS LIMITED (GB) | 2013-10-22 | — | — | US | disclosed |
| EP-2250161-B1 | COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY | ATOPIX THERAPEUTICS LTD (GB) | 2013-10-16 | — | — | EP | disclosed |
| US-8536158-B2 | Compounds having CRTH2 antagonist activity | ATOPIX THERAPEUTICS LIMITED (GB) | 2013-09-17 | — | — | US | disclosed |
| US-8168673-B2 | Compounds having CRTH2 antagonist activity | OXAGEN LIMITED (GB) | 2012-05-01 | — | — | US | disclosed |
| CN-101006055-B | 3-substituted-5-and 6-aminoalkyl indole-2-carboxylic acid amides and related analogs as inhibitors of casein kinase ie | AVENTIS PHARMA INC | 2011-06-22 | — | — | CN | disclosed |
| US-20110142855-A1 | Compounds Having CRTH2 Antagonist Activity | OXAGEN LIMITED (GB) | 2011-06-16 | — | — | US | disclosed |
| US-20100063103-A1 | Compounds Having CRTH2 Antagonist Activity | OXAGEN LIMITED (GB) | 2010-03-11 | — | — | US | disclosed |
| US-20100022613-A1 | Compounds Having CRTH2 Antagonist Activity | OXAGEN LIMITED (GB) | 2010-01-28 | — | — | US | disclosed |
| CN-100562521-C | Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase ie | AVENTIS PHARMA INC (US) | 2009-11-25 | — | — | CN | disclosed |
| WO-2009093026-A1 | COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY | OXAGEN LIMITED (GB) | 2009-07-30 | — | — | WO | disclosed |
| WO-2009093029-A1 | COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY | OXAGEN LIMITED (GB) | 2009-07-30 | — | — | WO | disclosed |
| US-20090192195-A1 | Compounds Having CRTH2 Antagonist Activity | OXAGEN LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| WO-2009090414-A1 | COMPOUNDS HAVING CRTH2 ANTAGONIST ACTIVITY | OXAGEN LIMITED (GB) | 2009-07-23 | — | — | WO | disclosed |
| US-20090186923-A1 | Compounds Having CRTH2 Antagonist Activity | OXAGEN LIMITED (GB) | 2009-07-23 | — | — | US | disclosed |
| CN-101006055-A | 3-substituted-5- and 6-aminoalkyl indole-2-carboxylic acid amides and related analogs as inhibitors of casein kinase iepsilon | AVENTIS PHARMA INC (US) | 2007-07-25 | — | — | CN | disclosed |
| CN-101001861-A | Substituted thienopyrrole carboxylic acid amides, pyrrolothiazole carboxylic acid amides, and related analogs as inhibitors of casein kinase i epsilon | AVENTIS PHARMA INC (US) | 2007-07-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192195-A1 | Compounds Having CRTH2 Antagonist Activity | HRH2, NR3C2, NR2C2 | HTR6 925/4885MEN1 4578/4885ALDH1A1 3417/4885 |
| US-20110142855-A1 | Compounds Having CRTH2 Antagonist Activity | HRH2, NR3C2, HRH4 | HTR6 653/4885MEN1 2925/4885ALDH1A1 4057/4885 |
| US-20140039012-A1 | Compounds Having CRTH2 Antagonist Activity | NR3C2, HRH2, NR2C2 | HTR6 641/4885MEN1 2985/4885ALDH1A1 4097/4885 |
| US-20090186923-A1 | Compounds Having CRTH2 Antagonist Activity | HRH2, HRH4, NR2C2 | HTR6 822/4885MEN1 4692/4885ALDH1A1 3449/4885 |
| US-20150246030-A1 | Compounds Having CRTH2 Antagonist Activity | NR3C2, HRH2, NR2C2 | HTR6 645/4885MEN1 2983/4885ALDH1A1 4087/4885 |
| US-20100063103-A1 | Compounds Having CRTH2 Antagonist Activity | HRH2, NR3C2, HRH4 | HTR6 653/4885MEN1 2925/4885ALDH1A1 4057/4885 |
| US-20100022613-A1 | Compounds Having CRTH2 Antagonist Activity | HRH2, NR3C2, HRH4 | HTR6 988/4885MEN1 4609/4885ALDH1A1 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.